Sandrine Egron
Investment Director at 50 Partners
Sandrine Egron
Investment Director at 50 Partners
France
Overview
Work Experience
Investment Director - 50 Partners Health
2022 - Current
50 Partners Health portfolio companies: Pixacare, Surge, Jeen, Ensweet, Gutycare, En Carta Diagnostics, Biohive, Glaaster, Medicud.
Board Member
2022
Co-founder and CEO Transition Advisor
2021 - 2022
Co-founder and CEO
2018 - 2021
Co-founded InnYTe with the aim of enhancing chronic disease management through digital health solutions in fast-developing countries. Worked alongside Prof. Anh Tuan Dinh Xuan, Chief Scientific Officer, and Philippe Nguyen, Chief Technology Officer. - Established InnYTe in Ho Chi Minh City, Vietnam, to address the significant need for healthcare innovation in a high smartphone penetration region. - Focusing on helping patients manage their conditions better and reducing hospital admissions caused by chronic disease complications, drawing on successful models from Western Innovation Hubs. --- - Developed the company's strategy, product line, and business model, ensuring practical alignment with users needs. (Initially tested prototypes at Vietnamese hospitals across breast cancer, ophthalmology, and COPD fields.) - Built and maintained relationships with global partners and funding organizations to support future growth. --- Served as the product owner, coordinating efforts between developers, designers, medical professionals, and QA specialists: - Oversaw all aspects of product design and development for 'TeamUP', a 360° Chronic Disease Management solution, and 'Doctors Answer'/'Bác sĩ giải đáp', an informational website for asthma and COPD patients. - Led user testing and incorporated feedback from quality assurance and regulatory affairs experts to improve product offerings. - Benefited from the guidance of an advisory board that included the Presidents of Vietnam's leading respiratory medical associations and Pr. Bousquet, Chairman of the WHO Global Alliance against Chronic Respiratory Diseases (GARD). --- - Organized a press conference in Ho Chi Minh City to launch 'Bác sĩ giải đáp', which received coverage in 17 articles and 3 broadcasts on HTV9, a leading news channel. - Prepared the ACETUP clinical trial to evaluate the efficacy and adoption of TeamUP among COPD patients at five public hospitals. Paused due to the Covid-19 outbreak.
Chief Operating Officer
2022 - 2022
Spent one month in Abidjan with the local team (across Yopougon, Cocody, and Abobo districts), preparing a mother and newborn healthcare services offer.
Leader Innovative Health Group
2019 - 2020
Appointed to guide the Innovative Health group, which includes 30 French healthcare companies active in Vietnam. - Led group sessions to foster collaboration. - Facilitated development of ties between Vietnamese teaching hospitals and French medical experts. - Supported the organization of “Healthcare Innovation Day” in Ho Chi Minh City, featuring renowned speakers such as Prof. Philippe Menasché on stem cells, Prof. Pierre Jaïs on AI in heart failure diagnostics, and Dr. Guillaume Charpentier on AI in diabetes treatment.
Life Sciences Consultant
2017 - 2018
Consultant for Startup Accelerators, Medtech Investors, and Consulting Firms. - Conducted technology due diligence on innovative medtech products for investors. - Facilitated partnership discussions with key industry players in Italy and Shanghai. - Developed comprehensive competitive benchmarking analyses for the respiratory care industry across European and South-East Asian markets.
Co-Founder
2016 - 2017
I joined two German scientists to start Vivosim and develop an AI-based invention in oncology. Vivosim AI is based on proprietary algorithms which can be used to improve drug dosing strategies along cancer treatment cycles, for higher efficacy and safety in each patient. - I spent time at the oncology departments of three teaching hospitals in Paris (Bichat, Tenon, Cochin) (Regularly attended multidisciplinary team meetings where complex patient cases are discussed) - Secured a pilot project in hemato-oncology with Innate Pharma (a listed biotech company specialized in immunotherapy) - Managed the pilot delivery, exceeding the expectations of Innate Pharma’s CMO and CTO
R&D Project Manager in Medical Device Development
2014 - 2016
At the Helmholtz Institute, Cardiovascular Engineering department (CVE): - Managed and worked on two main cardiovascular product development projects (prototyping, experimental validation, preclinical testing, partner relations, Quality Assurance) - Published seven articles and gave talks (in France, Germany, Poland) presenting independent research on the risks associated with cardiovascular interventions - Earned my PhD (Dr. rer. medic.) for this work - Supervised three Master’s Theses (students from Russia, China, and the US)
Business Development Manager
2013 - 2014
Nalys Healthcare division delivers services to the pharmaceutical industry in Quality Assurance, Quality Control, Regulatory Affairs, Production, and Engineering. - Drove new business opportunities: established trust relationships with clients (GSK and Pfizer), identified new projects, and designed tailored proposals. - Managed a team of consultants: project follow-ups and career management. - Sourced, interviewed, and hired additional team members as new projects were identified.
R&D Engineer in Medical Device Development (Master’s Thesis)
2012 - 2013
The heart valve team at the Helmholtz Institute (RWTH) was developing a customizable pulmonary valve prosthesis. - Invented and designed the stent customization system - Conducted mechanical tests - Assessed procedure feasibility
Education
Dr. rer. medic. (PhD)
2014 - 2017
Master's degree
2010 - 2012
Master's degree
2008 - 2010
Classes préparatoires
2007 - 2008